Patents by Inventor Thomas J. Simon

Thomas J. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240170162
    Abstract: Systems and methods are provided for treating an inflammatory or allergic response associated with a replicating pathogen, such as a virus in the coronaviridae family. The methods include emitting an electrical impulse near a vagus nerve within the patient sufficient to inhibit or reduce an inflammatory or allergic response in the patient, provide relief for bronchoconstriction that results in the tightening of airways and the inability to breath without ventilator support and/or lessen the abnormal blot clotting that develops in some patients. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.
    Type: Application
    Filed: December 21, 2023
    Publication date: May 23, 2024
    Inventors: Peter Staats, Thomas Errico, Joseph P. Errico, Bruce J. Simon
  • Patent number: 6649649
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 18, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada, & Co.
    Inventors: Stacia Kargman, Thomas J. Simon, Jilly Evans
  • Patent number: 6593361
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: July 15, 2003
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon
  • Publication number: 20020045605
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Application
    Filed: October 12, 2001
    Publication date: April 18, 2002
    Applicant: Merck & Co.
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon
  • Patent number: 5968974
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: October 19, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon